📌@aromicsbiotech, among the 175+ European companies that will present its advances in the 3th edition of @TechTourHQ Contest Final to an international audience of 350+investors, key corporates &innovation experts ▶️https://t.co/hy204evuZG
fantastic work in @sciencemagazine from our own @bobdleone about glutamine antagonism in cancer. double-edged sword that suppresses tumor metabolism and increases functionality of the TIL. #immunotherapy #immunometabolism
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat